Evidence map›Paper›PMID 42894386›Full record

ArticleBriefings in bioinformatics2026

Prediction of bacteria-specific drug metabolism using a cross-attention-based model.

Jaehyeon Park, Si Eun Kim, Heeyoung Yang, Nam-Chul Cho, Hyunho Kim, Hyun Kil Shin

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jaehyeon ParkDrug Information Platform Center, Chemical Platform Technology Division, Korea Research Institute of Chemical Technology (KRICT), 141, Gajeong-ro, Yuseong-gu, Daejeon 34114, Republic of Korea.ORCID 0009-0004-7459-809X
Si Eun KimChemical Analysis Center, Chemical Platform Technology Division, Korea Research Institute of Chemical Technology (KRICT), 141, Gajeong-ro, Yuseong-gu, Daejeon 34114, Republic of Korea.
Heeyoung YangCenter for Biomimetic Research, Korea Institute of Toxicology (KIT), 141, Gajeong-ro, Yuseong-gu, Daejeon 34114, Republic of Korea.
Nam-Chul ChoDrug Information Platform Center, Chemical Platform Technology Division, Korea Research Institute of Chemical Technology (KRICT), 141, Gajeong-ro, Yuseong-gu, Daejeon 34114, Republic of Korea.
Hyunho KimSchool of Artificial Intelligence, Chonnam National University, 77 Yongbong-ro, Buk-gu, Jeonnam Gwangju 61186, Republic of Korea.
Hyun Kil ShinDepartment of AI-Based Drug Discovery, Duksung Women's University, 33, Samyang-ro 144-gil, Dobonggu Seoul 01369, Republic of Korea.

Funding

Institute of Information & Communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (MSIT) IITP-2026-RS-2026-25619158Korea Institute of Toxicology 2710086911Korea Research Institute of Chemical Technology KK2652-10National Institute of Agricultural Science, Rural Development AdministrationNational Research Foundation of Korea RS-2021-NR057629National Research Foundation of Korea RS-2022-NR068434Research Program for Agriculture Science and Technology Development 004000007
6 · The paper itself

Abstract

Drug metabolism by gut microorganisms is bacteria-specific and can have clinically significant consequences, including prodrug activation, drug inactivation, and the generation of toxic metabolites. However, existing computational approaches have primarily focused on community-level predictions or drug-to-microbe effects, without resolving the metabolic contributions of individual bacterial strains or the bidirectional nature of drug-bacteria interactions, despite advances in computational frameworks. Here, we propose a bidirectional cross-attention architecture, multimodal Bi-MHA, that integrates atom-level molecular embeddings and protein-level bacterial embeddings from pretrained models to generate a combined representation for classification. The proposed model was developed using reliability stratification and a $\mathrm{\lambda}$-scaled loss function on the training dataset and achieved consistent performance across three unseen tasks: unseen drug (receiver operating characteristic area under the curve [ROC AUC]: 0.690), unseen bacteria (ROC AUC: 0.920), and unseen interaction (ROC AUC: 0.949), ranking first among all compared models in the rank-sum metric. Beyond prediction, attention-based analysis not only indicated enzymatic reaction sites that were experimentally validated in previous studies but also prioritized candidate bacterial proteins, demonstrating interpretability at both the atom and protein levels. The proposed model also achieved a 15 percentage point improvement in accuracy over the KNN baseline on an external validation dataset of 85 out-of-distribution drug-bacteria pairs. Furthermore, the model was extended to community-level prediction as a proof-of-concept application using a weighted-abundance pipeline on an independent microbiome dataset. These results demonstrate the model's potential as an interpretable screening tool for drug safety evaluation and personalized medicine. The source code is available at https://github.com/Jaehyeon-O-Ob/Bacteria-Specific_Drug_Metabolism.

Indexed as

BacteriaComputational BiologyGastrointestinal MicrobiomeModels, BiologicalHumansPharmaceutical PreparationsPharmaceutical Preparationsbacteria-specific drug metabolismbidirectional cross-attentiondrug-microbe interactiongut microbiomeinterpretabilitypersonalized medicine

Identifiers

PMID42894386
PMCPMC13677792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.